Sirtuin 1 (SIRT1) NAD + -dependent deacetylase regulates energy metabolism by modulating expression of genes involved in gluconeogenesis and other liver fasting responses. While many effects of SIRT1 on gene expression are mediated by deacetylation and activation of peroxisome proliferator activated receptor coactivator a (PGC-1a), SIRT1 also binds directly to DNA bound transcription factors, including nuclear receptors (NRs), to modulate their activity. Since thyroid hormone receptor b1 (TRb1) regulates several SIRT1 target genes in liver and interacts with PGC-1a, we hypothesized that SIRT1 may influence TRb1. Here, we confirm that SIRT1 cooperates with PGC-1a to enhance response to triiodothyronine, T 3 . We also find, however, that SIRT1 stimulates TRb1 activity in a manner that is independent of PGC-1a but requires SIRT1 deacetylase activity. SIRT1 interacts with TRb1 in vitro, promotes TRb1 deacetylation in the presence of T 3 and enhances ubiquitindependent TRb1 turnover; a common response of NRs to activating ligands. More surprisingly, SIRT1 knockdown only strongly inhibits T 3 response of a subset of TRb1 target genes, including glucose 6 phosphatase (G-6-Pc), and this is associated with blockade of TRb1 binding to the G-6-Pc promoter. Drugs that target the SIRT1 pathway, resveratrol and nicotinamide, modulate T 3 response at dual TRb1/SIRT1 target genes. We propose that SIRT1 is a gene-specific TRb1 coregulator and TRb1/SIRT1 interactions could play important roles in regulation of liver metabolic response. Our results open possibilities for modulation of subsets of TR target genes with drugs that influence the SIRT1 pathway.
Introduction
Thyroid hormone receptors (TRs) are members of the nuclear hormone receptor (NR) family [1] . Both TRs regulate gene transcription by binding to specific DNA sequences (thyroid hormone response elements, TREs) and nucleating formation of protein assemblies which, in turn, influence organization and posttranslational modification of nearby chromatin and RNA polymerase II recruitment and processivity [2] [3] [4] . TRs, like other NRs, harbor a hormone-dependent docking surface that binds several general coregulators, including the steroid receptor coactivator (SRC) family, TR associated protein 220 (TRAP220) and others, which are required for target gene induction by active thyroid hormone, predominantly triiodothyronine (T 3 ). Coregulators are recruited sequentially in a dynamic and ordered process and activated TRs are eventually ubiquitinated and channeled into proteasomal degradation pathways [5, 6] .
TR transcription complexes must also integrate responses to T 3 signals with those of other signaling pathways. TRs cooperate with particular subsets of heterologous DNA bound transcription factors (TFs) in composite modules, including CTCF [7] and SREBP1 [8] , and particular TR/TF combinations could be responsible for integration of different signaling pathways. TR coregulators could also play a role. For example, peroxisome proliferator activated receptor c coactivator 1a (PGC-1a) is induced in different tissues in response to a variety of different environmental signals and strongly potentiates TR activity [9] [10] [11] [12] [13] [14] [15] . In liver, PGC-1a is induced under fasting conditions and is required for optimal T 3 activation of genes involved in fatty acid boxidation, mitochondrial activity and other metabolic pathways [13] [14] [15] .
Sirtuin 1 (SIRT1) is an NAD + -dependent deacetylase that is activated by resveratrol and regulates the expression of genes involved in fasting response and resistance to metabolic diseases [16, 17] . SIRT1 regulates activity of several TFs that bind to PGC1a via targeted deacetylation of multiple PGC-1a lysine residues and enhancement of PGC-1a activity [18] . For example, SIRT1 enhances the activity of the NR PPARa in liver through PGC-1a [19] . In addition, SIRT1 binds directly to DNA bound TFs, including NRs, to influence TF activity [20] [21] [22] . For example, SIRT1 enhances the response of liver X receptor (LXR) a to agonists and this is accompanied by LXR deacetylation and SIRT1-dependent channeling of active LXRa into ubiquitindependent degradation pathways [20] .
There are superficial overlaps between the actions of TRs and SIRT1 in liver [16, 23] ; both factors exert similar effects upon genes involved in gluconeogenesis, fatty acid oxidation and mitochondrial function. Since TR binds PGC-1a [9] , we tested the possibility that SIRT1 may enhance activity of TRb1, the predominant TR subtype in liver, via effects upon PGC-1a activity. We confirm that SIRT1 synergizes with PGC-1a to potentiate T 3 response, in accordance with recent findings of another group [24] , but also find that SIRT1 enhances TRb1 activity independently of PGC-1a. More surprisingly, requirements for SIRT1 in T 3 response are highly gene-specific and, in one case, associated with hormone and SIRT1-dependent transcription complex assembly on DNA. We propose that TRb1/SIRT1 complex formation may serve as a checkpoint for regulation of key genes with important roles in metabolic response and our results open possibilities for modulation of subsets of T 3 dependent genes with drugs that target the SIRT1 pathway.
Materials and Methods

Plasmids and Reagents
Mammalian expression vectors for human TRb1 and PGC-1a and the bacterial expression vector for TRb1 (GST-TRb1) were described previously [9] . SIRT1 were cloned by PCR from a cDNA library of HepG2 cells in frame at BamHI and XbaI sites of pCDNA3Flag vector. The mammalian expression vectors for mouse SIRT1 wild type and SIRT1 mutant (H355Y) were provided as gifts from Dr. Tadahiro Kitamura (Gunma University). The DR-4-luc reporter plasmid was described previously [9] . The G-6-Pc-Luc reporter plasmid was constructed by cloning a G-6-Pc promoter region (22785 to 22358) into vector pGL4 basic (Promega). G-6-Pc promoter was generated by PCR amplification using two primer sets: forward, 59-CGGTACCTGAGCTCGC-TAGCCCTTTGAGAATCCACGGTGT-39, and reverse, 59-AAGCTTGGCCGCCGAGACCCTAACACTTGGGTCACG-39. The PCK1-Luc reporter plasmid was constructed by cloning a TRE located 13kb downstream from the 39 end of PCK1 (+18,719 to +19,603, +1 being the A base in the translation initiation codon) into vector pGL4.23 (Promega). The PCK1 promoter was generated by PCR amplification using two primer sets: forward, 59-CGGTACCTGAGCTCGCTAGCAACAATAGTGGCAGG-CATCC-39, and reverse, 59-AAGCTTGGCCGCC-GAGCCCTCCACAGAAGTCCACAT-39. The method for reporter construction was described previously [25] . SLC16A6-Luc (S710535) and MYH6-Luc (S704901) reporter plasmids were purchased from Switchgear Genomics.
Resveratrol (R5010), Nicotinamide (N3376), and MG-132 (C2211) were purchased from Sigma Aldrich.
Cell Culture and Transient Transfection
HepG2 cells stably expressing Flag tagged TRb1 were described previously [26] . 293T cells were purchased from ATCC (CRL-11268). 293T cells and Flag tagged TRb1 overexpressed HepG2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. Cells were plated in 24-well plates and transfected with expression plasmids, reporter plasmid, and control lacZ expression plasmid pCMV-b, by using Fugene HD Transfection reagent (Roche) according to manufacturer's instructions. Total amounts of expression vector plasmids were kept constant by the addition of appropriate amounts of empty pCMV vector. Cells maintained in 10% T 3 -stripped serum were treated with 10 nM triiodothyronine (T 3 ) for 24 h following transfection. Resveratrol or nicotinamide was added for 6 or 24 h prior to harvest. Luciferase and bgalactosidase activities were assayed as described [9, 25] .
Coimmunoprecipitation and Western Blot
Coimmunoprecipitations were performed from extracts of 293T cells that were cotransfected with 1 mg of Myc tagged TRb1 and Flag tagged SIRT1 expression plasmids. Cotransfected 293T Cells or Flag tagged TRb1 expressing HepG2 were treated +/2 10 nM T 3 for 12 h following transfection, and harvested in RIPA cell lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5 mM EGTA, 1% NP-40, Protease inhibitor cocktail (Roche). Wholecell lysate (400 mg) was incubated with 2 mg of anti-Flag (A2220) or anti-myc (A7470) antibody conjugated agarose bead slurry (Sigma Aldrich) for 12 h at 4uC. Antibody conjugated agarose beads were washed three times with RIPA buffer at 4uC, and bound proteins were separated by SDS-PAGE. Proteins were transferred to a PVDF membrane (Bio-Rad), subjected to Western blot analysis with anti-Myc (Sigma Aldrich M4439), anti-Flag (Cell Signaling #2044), anti-SIRT1 (Cell Signaling #2496), anti-TRb1 (Santa Cruz Biotechnology sc-738) and anti-GAPDH (Cell Signaling #2118), and then detected with an ECL kit (Amersham Pharmacia). Anti-acetylated-Lysine (Cell Signaling #9441) and anti-ubiquitin (Millipore MAB1510) antibodies were used to detect acetylation and ubiquitination of TRb1. Anti-PGC-1a antibody were purchased from Santa Cruz Biotechnology (sc-13067).
GST Pull-down
GST and GST-TRb1 fusions were expressed in Escherichia coli BL21 cells and isolated with glutathione-Sepharose-4B beads (GE Healthcare Life Sciences). Immobilized GST fusions were then incubated with SIRT1 protein produced by in vitro translation using the TNT-coupled transcription-translation system (Promega). Binding reactions were carried out in 250 ml of GST binding buffer (20 mM Tris-HCl, pH 7.9, 100 mM NaCl, 10 % glycerol, 0.05 % NP-40, 5 mM MgCl 2 , 0.5 mM EDTA, 1 mM dithiothreitol, and 1.5 % bovine serum albumin) for 4 h at 4uC. The beads were washed three times with 1 ml of GST binding buffer. Bound proteins were eluted by the addition of 20 ml of SDS loading buffer, and were analyzed by Western blot analysis using anti-SIRT1 antibody. Escherichia coli BL21 cells were purchased from Invitrogen.
Adenovirus Infection
Adenoviruses that express mouse wild type or mutant (H355Y) SIRT1 were kindly provided as gifts from Dr. Tadahiro Kitamura (Gunma University). Flag tagged TRb1 overexpressing HepG2 cells were infected with adenovirus expressing SIRT1 (AdSIRT1) or null adenovirus at multiplicity of infection = 50 and treated +/ 2 T 3 . Real-time PCR was performed as described previously [26] , using the Roche LightCycler 480 RT PCR machine and SYBR Green Mastermix (Roche) according to the manufacturer's procedure. Sequences of primers used for Real-time PCR are available upon request. Relative mRNA levels were calculated by comparative the cycle threshold method using GAPDH as the internal control. GAPDH level was not affected by T 3 .
Microarray Hybridization and Analysis
HumanHT-12 v4 whole genome expression arrays were purchased from Illumina. cRNA synthesis and labeling were performed using IlluminaH TotalPrep TM -96 RNA Amplification Kit (Ambion). Labeling in vitro transcription reaction was performed at 37uC for 14 h. Biotinylated cRNA samples were hybridized to arrays at 58uC for 18 h according to manufacturer's protocol. Arrays were scanned using BeadArray Reader. Unmodified microarray data obtained from GenomeStudio was background-subtracted and quantile-normalized using the lumi package [35] and analyzed with the limma package [36] within R [37] . All analysis was corrected for multiple hypotheses testing [38] , and effects determined to be significant when 2-fold with an adjusted pvalue 0.05. To facilitate comparisons among the various datasets, all data was uploaded into a SQLite3 database [39] . Heatmaps were produced and clustered using multiarray viewer [40] .
To determine T 3 -responsive gene transcripts affected by SIRT1 KD, we compared the T 3 -response in the NC-siRNA against SIRT1 siRNA through pattern analysis as done previously (26) . In brief, including the three affects (T 3 -response in NC-siRNA, T3-response in SIRT1 siRNA, and SIRT siRNA in the absence of T 3 ) a 3-by-3 permutation of down-regulated (0.5) and up-regulated (2) and no change (1) results in 27 possible patterns (supplemental). The Euclidean distance between experimental data and the 27 patterns were calculated, with the matching pattern receiving the minimal Euclidean distance.
Chromatin Immunoprecipitation (ChIP) Assay
Flag tagged TRb1 overexpressed HepG2 cells were transfected with SIRT1 siRNA or control siRNA and treated +/2 10 nM T 3 for 24 h following transfection. ChIP assays were performed by SimpleChip Enzymatic Chromatin IP Kit (Cell Signaling) according to manufacturer's instructions. 10 % (v/v) of the supernatant was saved as 'input' chromatin prior to immunoprecipitation. Anti-Flag antibody conjugated agarose bead slurry (Sigma Aldrich A2220) and anti-SIRT1 (Cell Signaling #2496) were used for immunoprecipitation. Immunoprecipitated DNA and input-sheared DNA were subjected to PCR using a primer pair for G-6-Pc (forward, 59-GAGGCGTCTCAGAAAACAGG-39, and reverse, 59-GCAGTGACCTCTGGGATGAG-39) or for PCK1 (forward, 59-AGTTTCTCCTCCTCCTGCAGACAA-39; and reverse, 59-AGGACCTGACCAGAAGTCAGAACA-39), which amplify regions spanning the thyroid response element (TRE). IgG was used as an immunoprecipitation control.
Microarray
Flag tagged TRb1 overexpressed HepG2 cells were transfected with control siRNA (100 nM) or SIRT1 siRNA (100 nM) and treated +/2 T 3 . Hybridizations and microarrays were performed as described previously.
Statistical Analysis
All results are the means 6 SD. Statistical analysis was performed using GraphPad Prism software (GraphPad Inc., San Diego, CA). Comparisons of groups were performed using a Student's t test. P , 0.05 was considered statistically significant. All experiments were performed at least three times.
Results
SIRT1 Enhances TRb1 Activity in PGC-1a Dependent and Independent Manners
To evaluate the possibility that SIRT1 modulates TRb1 activity, we examined SIRT1 effects on T 3 response at a standard T 3 inducible reporter driven by a TRE composed of a direct repeat of the consensus TR binding half-site AGGTCA (DR-4) [27] . We transfected the DR-4 reporter into HepG2 liver cells that stably express TRb1 +/2 expression vectors for PGC-1a and SIRT1 and measured T 3 effects on luciferase activity (Fig. 1A) . As expected, T 3 response was enhanced approximately 20-fold by PGC-1a whereas SIRT1 increased T 3 response 2.5 fold. Cotransfection of SIRT1 and PGC-1a resulted in synergistic increases in TRb1 activity; together, SIRT1 and PGC-1a potentiated T 3 response by greater than 200-fold, consistent with the notion that SIRT1 cooperates with PGC-1a to stimulate TRb1 activity [24] . Interestingly, SIRT1 overexpression had no obvious influence on acetylation of PGC-1a in these conditions, suggesting that SIRT1 must exert additional effects upon activity of the TRb1/PGC-1a complex (Fig. S1) .
We next examined effects of knockdown of endogenous PGC1a expression in the HepG2-TRb cells (Fig. 1B) . PGC-1a protein levels were greatly diminished after transfection of PGC-1a siRNA, as determined by western analysis of cell extracts (Fig. 1B, inset) . Under these conditions, however, SIRT1 coactivation of TRb1 was unaffected, and even, partially enhanced. Thus, SIRT1-dependent enhancement of T 3 response is independent of PGC-1a in this assay. SIRT1 enzymatic activity was required for TRb1 coactivation; a deacetylase defective mutant (H355Y) of SIRT1 did not enhance T 3 response (Fig. 1C) . We also verified that SIRT1 enhanced activity of both TR subtypes in transfections into 293T cells, which do not express endogenous TRs, albeit with a modest preference for TRb1 versus TRa1 (Fig. 1D ).
SIRT1 Interacts with TRb1
To investigate whether SIRT1 interacts with TRb1, we performed co-immunoprecipitations from extracts of 293 cells transfected with affinity tagged versions of SIRT1 (flag) and TRb1 (myc) to qualitatively assess SIRT1/TRb1 interactions in different conditions. SIRT1 precipitation with anti-flag antibody resulted in co-precipitation of myc-tagged TRb1 ( Fig. 2A) . Conversely, TRb1 precipitation with anti-myc antibody resulted in co-precipitation of SIRT1 (Fig. 2B) . Within this context, SIRT1/TRb1 interactions appeared unaffected by T 3 . We also performed co-immunoprecipitation assays in the HepG2 stably expressing TRb1 and showed that endogenous SIRT1 co-precipitated with TRb1 and, again, this effect was ligand-independent (Fig. 2C) . To test whether SIRT1 interacts with TRb1 in vitro, we performed glutathione-S-transferase (GST) pull-downs with purified bacterially expressed TRb1. As shown in Fig. 2D , 35 SMethionine-labeled SIRT1 protein was retained by GST-TRb1, but not by GST protein, in the absence and presence of T 3 . Thus, SIRT1 directly interacts with TRb1 in a ligand-independent manner.
SIRT1 Deacetylates TRb1 and Down-regulates TRb1 Protein Levels
To determine whether activity SIRT1 influences TRb1 acetylation state, we infected HepG2-TRb1 cells with an adenovirus expressing SIRT1 (adSIRT1) and treated with T 3 and immunoprecipitated TRb1. Western blot analysis with an acetyl lysine specific antibody (Fig. 3) confirmed that TRb1 is acetylated [28, 29] and also reveals that acetylation levels were specifically decreased in cells which overexpress SIRT1 and were treated with T 3 (Fig. 3) .
To determine how SIRT1 affects TRb1 protein levels, we decreased SIRT1 levels using a specific SIRT1 siRNA in HepG2-TRb cells. This treatment reduced SIRT1 mRNA and protein levels by more than 90% with no effect upon TRb1 mRNA levels ( Fig. 4A-C) . TRb1 protein levels were unaffected by SIRT1 knockdown in the absence of T 3 , however, there were T 3 -dependent reductions of TRb1 steady state levels and these were partially reversed in the presence of the SIRT1 siRNA (Fig. 4C) . Hormone activation usually results in diminished steady state levels of nuclear receptors and this phenomenon reflects increased ubiquitin-dependent receptor turnover; an essential step for renewal of NR transcription complexes [5] . Over the course of the study, T 3 consistently reduced steady state TRb levels, although the extent of this effect varied from modest (20%) to large (.80%). In this case, effects were large and we also observed that this effect was partly dependent upon SIRT1 enzymatic activity; wild type SIRT1 potentiated T 3 -dependent decreases in TRb1 levels in transfected 293T cells but no decrease was observed in the presence of the deacetylase-defective mutant of SIRT1 (Fig. 4D) . Nicotinamide, a SIRT1 inhibitor, also reversed T 3 -dependent reductions in TRb1 levels in this cell type (Fig. 4E) . This is consistent with the idea that SIRT1 activity is required for hormone-dependent reductions in TRb1 steady state levels in these conditions, although nicotinamide may also slightly reduce SIRT1 levels and this could also contribute to this effect. We conclude that SIRT1 enhances T 3 -dependent reductions in TRb1 steady state levels.
Since previous studies suggested that SIRT1 dependent deacetylation of LXRs is associated with enhanced ubiquitindependent receptor turnover [20] , we examined effects of inhibition of proteasome activity upon TRb1 steady state levels and ubiquitination. In the absence of T 3 , TRb1 protein levels were not changed by SIRT1 overexpression, treatment of proteasome inhibitor (MG132), or both in transfected 293T cells (Fig. 5A) . In the presence of T 3 , however, treatment with MG132 led to increases in TRb1 levels relative to that seen with overexpressed SIRT1 and T 3 (Fig. 5A) . Overexpression of SIRT1 was also associated with accumulation of higher molecular weight ubiquitinated forms of TRb1, similar to that seen in the presence of proteasome inhibitor MG132 (Fig. 5B) . Thus, SIRT1 overexpression results in T 3 -dependent deacetylation of TRb1 and enhanced proteasome-mediated degradation and ubiquitination of TRb1.
SIRT1 Influences Expression of a Subset of TRb1 Target Genes
To understand how knockdown of SIRT1 would influence expression of TRb1 target genes involved in fasting responses, we examined effects of transfected SIRT1 siRNA on T 3 response in HepG2-TRb cells using qPCR analysis of selected TRb1 targets [26] . SIRT1 siRNA treatment led to complete loss of T 3 induction of the glucose 6 phosphatase (G-6-Pc) gene, which encodes an enzyme that catalyzes a key rate limiting step in gluconeogenesis (Fig. 6A) . In fact, T 3 suppressed G-6-Pc mRNA levels in the presence of SIRT1 siRNA relative to basal levels seen with SIRT1 siRNA alone. SIRT1 also modestly inhibited T 3 induction of two other fasting response genes, phosphoenol pyruvate carboxykinase 1 (PCK1) and fibroblast growth factor 1 (FGF21) (Fig. 6B, C) . However, T 3 induction of other target genes, including Hairless (HR; Fig. 6D ), was completely unaffected by SIRT1 knockdown. PGC-1a knockdown only slightly decreased mRNA level of these target genes, G-6-Pc and PCK1 (Fig. S3) . This finding strengthens the suggestion that SIRT1-dependent regulation of these genes is independent of PGC-1a in these assay conditions.
To explore the influences of SIRT1 knockdown upon T 3 response more fully, we examined T 3 induction +/2 SIRT1 siRNA in HepG2-TRb1 cells using an array based assay. As we documented previously [26] , hundreds of genes displayed significant T 3 response in this cell type, with most induced by T 3 and a minority repressed (Fig. S2) . However, SIRT1 siRNA treatment only inhibited T 3 induction of a small subset of these TRb1 target genes (Fig. 7) with the vast majority unaffected by SIRT1 (Fig. S2) . There is no obvious defined functional association among the affected genes (i.e., functional ontology; not shown). Thus, SIRT1 is absolutely required for T 3 -induction of a very limited number of genes.
SIRT1 Potentiates TRb1 Activity at Native Regulatory Elements
To examine effects of SIRT1 on TRb1 activity at native TREs in the G-6-Pc and PCK1 genes, we used computer aided analysis to localize potential regulatory elements in both loci. For the G-6-Pc gene, we detected a hitherto unknown DR-4 site approximately 2.3 kb upstream of the transcriptional initiation site (Fig. 8A) . While previous studies suggested that the rodent PCK1 proximal promoter harbors a variant TRE [30] [31] [32] , we were unable to locate functional TREs within the human PCK1 proximal promoter or demonstrate TRb1 interaction with this region of DNA by transfection analysis or gel shift (not shown). However, we did localize a previously unknown non-canonical DR-4 site around 13KB downstream of the gene (Fig. 8A) .
As expected, TRb1 conferred T 3 response upon reporters driven by the native G-6-Pc promoter and the PCK1 downstream TRE (Fig. 8B, C) . This effect was enhanced by SIRT1 cotransfection (Fig. 8B, C) and, conversely, SIRT1 knockdown inhibited T 3 response in both contexts (Fig. 8D, E) . However, effects of SIRT1 overexpression and knockdown were more prominent at the G-6-Pc promoter versus the PCK1 downstream (Fig. 8 ) and other native TREs (not shown), in parallel with strong SIRT1 requirements for T 3 induction of the native G-6-Pc gene. T 3 treatment and SIRT1 overexpression did not alter activity of the parental pGL4.23 reporter, indicating that effects were specific to G-6-Pc and PCK1 sequences (Fig. S4B) .
To directly compare SIRT1 effects upon T 3 response at TREs that localized to proximal promoters, analogous to G-6-Pc, and to rule out the possibility that the relative lack of a SIRT1 effect upon PCK1 was a consequence of the unusual source and composition of this element, we also assessed SIRT1 effects upon proximal promoters of other TRb1 target genes (Fig. S4C, D) . While SIRT1 potentiated T 3 response at the SLC16A6 and MYH6 promoters, the extent of SIRT1 potentiation was promoter-specific with relatively modest effects at SLC16A6 and stronger effects upon MYH6 (Fig. S4C, D) . Thus, SIRT1 enhances TRb1 dependent T 3 response in a promoter-specific action.
To verify that TRb1 and SIRT1 co-localized to the G-6-Pc and PCK1 TREs in cultured HepG2-TRb1 cells, ChIP analysis was performed (Fig. 9A, B) . We observed that TRb1 (using an antibody to the Flag-tag at the N-terminus of TRb1 expressed in these cells) and SIRT1 were present at both elements in the absence of hormone and SIRT1 siRNA knockdown reduced the amount of detectable SIRT1 protein at both TREs. Unlike many previously documented cases of hormone-independent interactions of TRs with TREs [1] , T 3 enhanced TRb1 binding to the G-6-Pc promoter. SIRT1 recruitment to the G-6-Pc TRE also appeared hormone-dependent, even though TRb1/SIRT1 interactions are unaffected by T 3 . More surprisingly, SIRT1 knockdown inhibited T 3 -dependent TRb1 interactions with the G-6-Pc promoter. T 3 weakly enhanced TRb1 and SIRT1 binding to the PCK1 TRE and SIRT1 knockdown reversed the hormonedependent component of this interaction. Thus, SIRT1 is recruited to TRE region of TRb1 target genes and is required for T 3 -dependent association of TRb1 with the G-6-Pc promoter and, to a lesser extent, the PCK1 downstream TRE.
Drugs that Target SIRT1 Modulate TRb1 Activity
Finally, we determined whether TRb1 action at dual TRb1/ SIRT1 target genes was influenced by drugs that target the SIRT1 pathway. Treatment of HepG2-TRb1 cells with resveratrol, an indirect activator of SIRT1, did not affect basal mRNA levels of G-6-Pc, but did enhance T 3 response (Fig. 10A) . In parallel, resveratrol enhanced basal PCK1 and FGF21 mRNA levels and also potentiated T 3 response at both genes (Fig. 10B, C) . Treatment of HepG2-TRb1 cells with the SIRT1 inhibitor nicotinamide potently inhibited T 3 induction of G-6-Pc (Fig. 10D) , similar to effects of SIRT1 siRNA treatment. In parallel, nicotinamide modestly inhibited T 3 response at PCK1 and FGF21 (Fig. 10E, F) . Thus, chemical manipulation of SIRT1 influences T 3 response and these SIRT1-dependent effects display similar gene context-specificity to that seen with SIRT1 siRNA.
Discussion
In this study, we have investigated interactions of SIRT1 and TR signaling pathways. We hypothesized that PGC-1a and SIRT1 would cooperate to enhance TRb1 activity in liver cells and, accordingly, we find that PGC-1a and SIRT1 synergize to potentiate T 3 response at a TRE-dependent reporter, a very large enhancement of T 3 activation in response to coregulator transfection compared with previous studies [9, 33] . Similar findings were recently reported by another investigator [24] , who also demonstrated that SIRT1 promotes T 3 -dependent deacetylation of PGC-1a and that SIRT1 is required for optimal T 3 response of endogenous TR-regulated genes in cultured liver cells, liver primary cultures and native rat liver. We have also obtained other evidence which suggests, however, that effects of SIRT1 are not completely dependent upon PGC-1a and that SIRT1 is also a direct TRb1 coactivator. SIRT1 binds to TRb1 in co-immunoprecipitation experiments and in vitro pulldowns and ChIP studies demonstrate colocalization of TRb1 and SIRT1 at TREs located near target genes and similar results were also seen by Thakran and colleagues [24] . Furthermore, SIRT1 potentiates T 3 response at a transfected reporter in the absence of exogenous PGC-1a and this effect is actually potentiated by knockdown of endogenous PGC-1a. Additionally, knockdown of endogenous PGC-1a does not diminish T 3 response at two endogenous genes, opposite to effects of knockdown of SIRT1, implying that T 3 response is PGC-1a independent in these conditions. Finally, SIRT1 overexpression triggers TRb1 deacetylation and enhanced T 3 -and ubiquitin-dependent turnover of TRb1. We acknowledge the possibility that SIRT1 could influence TRb1 indirectly in the absence of PGC-1a, through actions upon another TR cofactor such as PGC-1b or other TR interacting proteins. However, correlation between SIRT1 enhancement of TRb1 activity and SIRT1/TRb1 interactions leads us to suggest that SIRT1 can modulate in two ways; indirectly, via potentiation of PGC-1a activity, and directly through TRb1 contact.
While SIRT1 is a direct TR cofactor, requirements for SIRT1 in T 3 response appear different from general TR coregulators such as the SRCs and TRAP220, which are needed for T 3 activation of most TRb1 target genes [3] . Instead, SIRT1 enhances TRb1 activity in a strongly gene-specific manner. We found that SIRT1 knockdown abolished T 3 induction of G-6-Pc, but only modestly inhibited T 3 induction of the PCK1 and FGF21 genes, and left T 3 response at HR and other genes completely unaffected. These results were internally consistent with experiments that utilized a small molecule activator (resveratrol) or an inhibitor (nicotinamide) of the SIRT1 pathway. Array based analysis of effects of SIRT1 knockdown in HepG2-TRb cells confirmed that most T 3 responses were independent of SIRT1, but also revealed that a small subset of TRb1 target genes were strongly inhibited by SIRT1 knockdown. Studies of Thakran et al. are also indicative of gene specificity in TRb1/SIRT1 cooperation [24] . Whereas T 3 and resveratrol synergized to activate the pyruvate dehydrogenase kinase 4 (PDK4) gene in HepG2 cells, they only displayed modest additive effects at carnitine palmitoyl transferase 1a (CPT1a), and resveratrol did not enhance T 3 response at other genes.
How does SIRT1 modulate TRb1 activity? SIRT1 binds TRb1 in a hormone-independent fashion. This is different from general coactivators such as the SRCs which interact with a liganddependent activation function (AF-2) in the receptor ligand binding domain [3, 33] and could imply that SIRT1 plays a distinct role from other TR coregulators. SIRT1 nevertheless largely influences T 3 response, with only modest effects upon unliganded TRs in some conditions, implying that it must cooperate with factors that act upon T 3 -liganded TRs. There are also close parallels between effects of SIRT1 upon TRb1 activity, acetylation state and turnover (this study) and previously reported effects of SIRT1 on LXRa [20] . In the latter study, the authors proposed that LXRs first induce the target gene in response to activating ligands and that SIRT1 subsequently deacetylates LXRa to trigger its ubiquitination and turnover, thereby allowing novel transcription complex formation. We have not investigated kinetics of changes in TRb acetylation state through the transcription cycle, but it seems reasonable to suggest that SIRT1 could fulfill a similar function for TRs. TR acetylation is mediated by histone acetyl transferases (HATs) such as CBP/ p300, among the first factors recruited to target genes after T 3 binding [28] . We therefore suggest that SIRT1 must act at an essential step of TRb1 activation that occurs after CBP/p300 dependent acetylation and that separate acetylation and deacetylation steps may be important components of the transcription cycle. To fully investigate this idea, it will be important to understand kinetics of recruitment of different cofactors that, respectively, acetylate and deacetylate TRs, the role of different TR acetylation sites in T 3 response and the correlation of these events with TR acetylation status and transcriptional activity.
Data mentioned above describe general effects of SIRT1 upon TRb activity, modification state and turnover, but it is hard to completely reconcile these effects with occasional strong genespecific requirements for SIRT1 in T 3 response. We instead propose that gene-specific effects of SIRT1 upon T 3 response may be related to additional effects upon TRb1 transcription complex formation. Three lines of evidence support this idea. T 3 enhances SIRT1 recruitment to the G-6-Pc TRE. This is unexpected; TRb1/SIRT1 interactions appear independent of hormone ( Fig. 2) . Further, T 3 strongly enhances TRb1 binding to the G-6-Pc promoter in cultured cells. This is also unusual; previous ChIP studies indicated that TRb/TRE interactions are usually unaffected by T 3 . Finally, T 3 -dependent TRb1 binding to the G-6-Pc promoter is potently inhibited by SIRT1 knockdown. We do not know of any other case in which TRb1/TRE interactions in cultured cells are dependent upon a cofactor. Together, these observations suggest that T 3 must trigger steps involved in TRb/ SIRT1 complex assembly on the G-6-Pc TRE. Interestingly, absolute requirements for SIRT1 in T 3 response of G-6-Pc were recapitulated in transfections with a G-6-Pc promoter dependent reporter. Thus, information required for strong SIRT1 dependence of T 3 response is located within this segment of DNA. It may be interesting to consider contributions of other TFs that bind the G-6-Pc promoter and cooperate with TRb1 and/or SIRT1 in these effects and the possibility that TRb1 acetylation inhibits TRb binding in this context.
The possible physiologic significance of TRb1/SIRT1 interactions is not completely clear. Given that PGC-1a is induced in fasting and that SIRT1 mediates beneficial effects of calorie restriction, it is reasonable to suggest that a TRb1/PGC-1a/ SIRT1 complex may be required for acute T 3 response of genes involved in gluconeogenesis and fatty acid b-oxidation in liver [24] . Results of our experiments add another angle, strong SIRT1 requirements for responses of particular T 3 regulated genes, including those seen at the G-6-Pc locus in this study and the PDK4 locus in another investigation [24] also raises the possibility that TRb1/SIRT1 complex formation is an essential checkpoint for acute T 3 regulation of particular subsets of genes in vivo. Another recent study reveals inverse correlation between thyroid hormone status and SIRT1 protein levels (but not mRNA levels) and SIRT1 activity in liver [41] . Given that physiological adaptation to fasting involves suppression of thyroid hormone actions, the authors suggest that increases in SIRT1 protein may be a specific response to reduced thyroid hormone status during caloric restriction. Our studies show that SIRT1 can exert PGC1a independent effects on TRb1, but we do not determine whether similar SIRT1 dependent effects on TRb1 also occur in the presence of PGC-1a, whether these effects occur in mouse liver or precise physiologic conditions in which SIRT1 directly influences TRb1. Thus, it is not obvious how molecular mechanisms described here may be involved in physiologic responses to fasting or hyperthyroidism. One interesting possibility, however, is that gene-specific SIRT1/TRb1 interactions could preserve subsets of T 3 regulated responses in conditions in which thyroid hormone levels and signaling pathways are broadly suppressed by starvation or fasting. We also note that thyroid hormone regulation of liver metabolic genes differs in different conditions; for example, thyroid hormone induction of gluconeogenic genes seen here in cell culture models can also be observed in mouse liver in some conditions but not others [42, 43] . It will be interesting to define the role of TRb1/SIRT1 interactions in these phenomena. Given the general roles of SIRT1 in TRb activity, acetylation and turnover that resemble those seen with LXRa and PPARc [20, 44] and the additional gene-specific roles of TRb/ SIRT1 interactions, it will also be important to understand what types of effects are active in different types of physiological response to changes in TRb1 or SIRT1 levels or actvity.
Regardless of the precise function of TRb1/SIRT1 interactions, the fact that we can modulate T 3 response at several endogenous genes with ligands that alter SIRT1 activity, resveratrol and nicotinamide, suggests that it may be possible to selectively manipulate subsets of key T 3 responsive genes in vivo with combinations of thyromimetics and SIRT1 ligands. For example, SIRT1 activators could be used to enhance T 3 -dependent fatty acid oxidation in liver and a SIRT1 inhibitor could inhibit excessive gluconeogenesis associated with thyroid hormone excess states. These possibilities should be tested in animal models and could form the basis for novel therapeutic approaches to metabolic disease that employ SIRT1 modulators in combination with several thyromimetics that exhibit improved safety profiles relative to native thyroid hormones [34] . 
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